Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer

Xiaoran Liu(Peking University), Huiping Li(Peking University)
British Journal of Cancer
March 22, 2024
10.1038/s41416-024-02610-0
Cited by 0

Related Papers

Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast Cancer
|New England Journal of Medicine|2024|235
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
|Nature Communications|2018|106
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
|BMJ|2023|82
Peripheral CD8+CD28- T cell level reflects tumor immunity and could predict anti- HER2 based therapy response in metastatic breast cancer
|Research Square|2022|0